HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Glycogen storage disease type III in the Irish population.

Abstract
Glycogen storage disease type III (GSD III) results from mutations of the AGL gene encoding the glycogen debrancher enzyme. The disease has clinical and biochemical heterogeneity reflecting the severity of the AGL mutations. We sought to characterise the molecular defects in our cohort of Irish patients with GSD III. Fifteen patients from eight unrelated Irish families were identified: six males and nine females. The age ranged from 2-39 years old, and all presented in the first 3 years of life. Four patients (of three families) had mild disease with hepatomegaly, mild hypoglycaemia and normal creatine kinase (CK) levels. Five families had more severe disease, with liver and skeletal muscle involvement and elevated CK. Eleven different mutations were identified amongst the eight families. Of the 11, six were novel: p.T512fs, p.S736fs, p.A1400fs, p.K1407fs, p.Y519X and p.D627Y. The family homozygous for p.A1400fs had the most severe phenotype (early-onset hypoglycaemia, massive hepatomegaly, myopathy and hypertrophic cardiomyopathy before age 2 years), which was not halted by aggressive carbohydrate and protein supplementation. Conversely, the only missense mutation identified in the cohort, p.D627Y, was associated with a mild phenotype. The phenotypic diversity in our GSD III cohort is mirrored by the allelic heterogeneity. We describe two novel null mutations in exon 32 in two families with severe GSD III resistant to current treatment modalities. Knowledge of the specific mutations segregating in this cohort may allow for the development of new therapeutic interventions.
AuthorsEllen Crushell, Eileen P Treacy, J Dawe, M Durkie, Nicholas J Beauchamp
JournalJournal of inherited metabolic disease (J Inherit Metab Dis) Vol. 33 Suppl 3 Pg. S215-8 (Dec 2010) ISSN: 1573-2665 [Electronic] United States
PMID20490926 (Publication Type: Journal Article)
Chemical References
  • Glycogen Debranching Enzyme System
  • amylo-1,6-glucosidase
Topics
  • Adolescent
  • Adult
  • Child
  • Child, Preschool
  • DNA Mutational Analysis
  • Disease Progression
  • Female
  • Founder Effect
  • Genetic Association Studies
  • Genetic Predisposition to Disease
  • Glycogen Debranching Enzyme System (deficiency, genetics)
  • Glycogen Storage Disease Type III (diagnosis, enzymology, epidemiology, genetics, therapy)
  • Heredity
  • Heterozygote
  • Homozygote
  • Humans
  • Infant
  • Infant, Newborn
  • Ireland (epidemiology)
  • Male
  • Mutation
  • Pedigree
  • Phenotype
  • Severity of Illness Index
  • Treatment Outcome
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: